NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Dynavax Technologies Corporation (DVAX) Stock Analysis

Dynavax Technologies Corporation (DVAX) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

DVAX

$15.50

$0.00 (0.00%)

Last trade February 10, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DVAX with… →

DVAX Key Statistics

As of Feb 10, 2026
Trading
Open
$0.00
Previous Close
$15.50
52-Week Range
9.20–15.73
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.93
Valuation
Market Cap
$1.82B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
46.97
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.51
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.37
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
−13.13%
1-Year Return
+17.42%
Dividend and dates
Avg Volume
3.08M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DVAX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.78%
2025+20.44%
2024 (partial year)+0.08%

As of February 10, 2026.

DVAX Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricDVAXDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio5.512.30140% above
Profit margin−13.13%−3.14%10.0 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Dynavax Technologies Corporation (DVAX) carries a market capitalisation of $1.82B. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 405 employees.

The 52-week range on file runs from $9.20 to $15.73. The most recent close on file for DVAX is $15.50, dated February 10, 2026. The close was unchanged from the previous session. The latest close sits 68.48% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $330.51M. The reported profit margin is −13.13%. That is 10 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.37.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 46.97. The price-to-sales ratio is 5.51. On price-to-sales that is 139.82% above the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

The reported beta is 0.93. Annualized volatility over the trailing 1 year is 51.29%. Over the trailing twelve months the price has returned +17.42%.

Growth & Income

The record shows no dividend for DVAX.

The record holds one complete calendar year, 2025, which returned +20.44%. 2026 is still running; the price is +0.78% year to date.

Peer Comparison

Dynavax Technologies Corporation (DVAX) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Dynavax Technologies Corporation DVAX $1.82B —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Dynavax Technologies Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of February 10, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Dynavax Technologies Corporation

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Visit website →